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Abstract
Objectives: Physical pain is a known symptom in amyotrophic lateral sclerosis (ALS), but no systematically derived preva-
lence estimate is available. The aim of this study was to determine the pooled prevalence of pain in ALS, relative to its
method of measurement and pain characteristics. Methods: A systematic search across multiple databases was conducted
on January 16, 2020. Random-effects meta-analyses of single proportions were performed on prevalence data.
Heterogeneity was determined using the I2 statistic. Where available, pain location, intensity, and type or source were
compared. Results: 2552 articles were identified. Twenty-one eligible studies were included. All studies used observa-
tional designs (14 cross-sectional, 6 cohort, 1 case-control). Pooled prevalence of pain in ALS across all studies was
60% (95% CI ¼ 50–69%), with a high degree of heterogeneity (I2 ¼ 94%, p < .001). Studies that used only validated
measures had lower heterogeneity (I2 ¼ 82%, p¼ 0.002), compared to those that used tailored measures, or tailored sup-
plemented with validated measures (I2 ¼ 90%, p<0.001 and I2 ¼ 83%, p<0.001, respectively). In a subset of studies
(N¼9), the most commonly reported pain location was the upper limbs including shoulders/extremities (41.5%). A fur-
ther study subset (N¼ 7) showed moderate-severe intensity pain was most frequently reported. Type of pain was com-
monly related to cramp or spasm. Conclusions: Experiencing physical pain in ALS occurs with high prevalence. Deriving
consensus on which specific tools should be used to assess, monitor and compare symptoms of pain in this population
will reduce current heterogeneity in approaches and increase the likelihood of ameliorating distressing experiences more
effectively.
keywords: Pain, amyotrophic lateral sclerosis, motor neurone disease, meta-analysis
Introduction
Pain is an important and common symptom in
patients with amyotrophic lateral sclerosis (ALS)
(1–3). It has many causes; it is likely that more
than one type may occur in any individual. Types
of pain include: muscle cramp, neuropathic pain,
joint pain, muscle and fibrous tissue pain, or pain
from intervertebral disk protrusion or spondylosis
exacerbated by or associated with postural disturb-
ance (2,4). In the UK, the National Institute for
Health and Care Excellence (NICE) guidelines do
not address the issue of pain in ALS management
(5) as there is limited research on the effectiveness
of treatment (6,7). In ALS, research has shown
that pain can impact on an individual’s life across
physical, psychological, social, and spiritual
domains (3). It is an important symptom requiring
palliation within specialist multidisciplinary ALS
care (8).
Studies estimating prevalence of pain in ALS
have produced a wide range of results suggesting
rates as low as 15% to as high as 85% (2,4). While
reviews have been conducted in the area of pain in
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ALS (e.g., (2,4)), there are currently no systematic
reviews or meta-analyses to determine specifically
the prevalence of pain, its detection, and associ-
ated features in ALS. Previous research suggested
that improvements are needed to standardize
assessments to help target pain management prac-
tices (9). A more thorough understanding, meas-
urement, and quantification of pain in ALS is
needed to improve clinical practice.
The primary aim of this study was to systematic-
ally determine the pooled prevalence of pain in ALS.
The secondary aims were to explore the common
evaluation characteristics of pain (such as location,
intensity, and type of pain), and account for the type
of methods used in measuring pain in ALS.
Methods
The systematic review was conducted in accord-
ance with the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA)
reporting guidelines (10).
Search strategy and eligibility criteria
The searches included both medical subject headings
(MeSH) and keyword terms (with spelling variants),
for the condition of ALS (“Amyotrophic Lateral
Sclerosis” OR “Motor Neurone Disease” OR “Motor
Neuron Disease” OR “Lou Gehrig’s Disease”) AND
the symptom of pain (“Pain”). Eligibility criteria were
primary research studies or secondary data analysis
that included pain prevalence data for people with a
diagnosis of ALS above the age of 18. Exclusion crite-
ria were case-studies, editorials and letters to the edi-
tor, grey literature, and conference proceedings.
Searches were restricted to the English language.
Information sources
The following databases were searched systematically
from inception to 1st February 2019: MEDLINE
and Embase via OVID, Cochrane CENTRAL,
CINAHL, AMED, PsycINFO, and Scopus. Scopus
was used as a citation tracking tool to supplement
database searches. The searches were updated on
16th January 2020 using the same databases.
Study selection and data extraction
In Stage 1, the search strategy was codesigned by
all authors. The initial database searches were per-
formed by author N.H., and duplicate results were
removed. In Stage 2, a reviewer (author N. H.)
screened titles and abstracts to determine article
eligibility and applying exclusion criteria for the
full-text review (Stage 3). Any articles marked as
uncertain for inclusion in Stage 2 were automatic-
ally progressed for full article screening (Stage 3)
using the eligibility and exclusion criteria. Stage 3
(full article review) was conducted by the same
reviewer (author N. H.). Any full-text articles
marked as uncertain for inclusion were reviewed
by 2 additional members of the review team
(authors R. R. and G. P.) until consensus was
determined. All final papers were additionally
reviewed (author R. R.) before final inclusion.
Data extracted from full-text articles included
the study design, sample size, sample source, pain
assessment method, male/female ratio, average age,
and pain prevalence estimate. Where available,
data on location of pain, type of pain, and its
intensity were extracted. For longitudinal studies,
only baseline data was extracted in order to stand-
ardize prevalence comparisons.
Quality assessment
All included full-text articles were assessed for
quality by one reviewer (N. H.) and moderated by
an additional reviewer (R. R.) using either the
Appraisal Tool for Cross-sectional Studies (AXIS)
(11) or the Critical Appraisal Skills Programme
(CASP) Study checklist (12).
Statistical analyses
Extracted data and quality assessment ratings
underwent descriptive comparison. The meta
package within R Software (13) was used for ran-
dom-effects meta-analysis of single proportions for
prevalence estimates, and to create forest plots of
the data (14). The Cochranes Q (v2) test and I2
statistic was used to estimate what percentage of
the variation across studies is due to heterogeneity
rather than chance. An I2 value of >75% suggests
considerable heterogeneity (15). 95% confidence
intervals (CI) were calculated alongside the preva-
lence of pain statistic (16). An additional explora-
tory subgroup analysis of the types of pain
measures used was performed. Measures were
classified as either validated (e.g., structured
scales/measures/questionnaires), tailored (e.g.,
interviews/single questions/multiple questions), or
tailored supplemented with validated measures.
Where available, data were pooled to describe
the total number of participants per location of
pain and re-classified into three specific data-
driven regional categories: head/neck/trunk/back,
upper limbs including shoulders/extremities, and
lower limbs including extremities. Upper limb
extremities included fingers and hands, and lower
limb extremities included toes and feet. In ambigu-
ous cases where the location of pain was uncertain
or distributed across multiple regions (i.e., “upper/
lower limbs”), these were allocated to all relevant
location categories to ensure inclusivity and avoid
underestimation for specific locations. The propor-
tion for each specific region was calculated by
summing the number of individuals reporting the
specific pain locations (i.e., head/neck/trunk/back)
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and dividing it by the sum of all individuals report-
ing pain locations over all studies, multiplied by
100. This produced a percentage per region. The
formula is presented below:P
N of Specific Pain Locationð ÞP
N of All Pain Locationsð Þ
 
 100
¼ % Pain in Specific Region
Where reported, pain intensity data were
extracted and reclassified into “mild”, “moderate”,
“severe”, and “very severe” intensity categories
where necessary. Percentages were calculated for
each category using this formula:
P
N of Specific Pain Intensity Categoryð ÞP
N of All Pain Intensity Categoriesð Þ
 
 100
¼ % Specific Pain Intensity Category
Results
Search results
Figure 1 shows the full screening process. The ini-
tial and updated searches identified 2552 articles,
with 172 full-text articles screened for eligibility,
where less than 5% of those were reviewed by add-
Figure 1. Prisma Flowchart (10).
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itional team members for inclusion. Twenty-one
studies were found to meet the inclusion criteria
(17–37). Table 1 shows summary details of all
included studies. Of the 21 studies included, all
were observational studies; 14 used a cross-sec-
tional design (17,20,21,23–27,29,30,32,33,35,37),
six used a cohort design (18,19,22,28,31,34) and
one case control study (36). The studies yielded a
total of 3601 ALS patients with study sample sizes
ranging from 7 to 2092 participants with the
median sample size of 46 (inter quartile range ¼
64). There was an overall heterogeneity of pain
assessment methods, including validated question-
naires, combinations of questions from validated
scales, retrospective medical record review, and
single-item questions (both with and without add-
itional validated measures). The most commonly
used validated measure used was the Brief Pain
Inventory (BPI) but this was only in N¼ 4 of the
included studies.
Summary of quality assessment
Overall, the eligible studies were of adequate qual-
ity, with clear aims/objectives, descriptions of study
populations, and justifiable results and findings.
Issues emerged regarding justification of sample
size, measurement of confounds, use of valid, and
standardized outcome measures (of pain), meth-
odological clarity, and follow-up with participants.
Quality ratings for all included studies can be
found in Supplementary Table 1.
Prevalence of pain
All included studies (N¼ 21) provided data for the
prevalence of pain in ALS. Figure 2 presents a for-
est plot of all nineteen articles included in the
meta-analysis, illustrating the substantial hetero-
geneity of overall results (I2 ¼ 94%, p< 0.001).
The overall pooled pain prevalence across all
included studies was 60% (95% CI ¼ 50–69%),
Figure 2. Forest Plot of pooled prevalence of pain in ALS across all studies (N¼21), including pooled prevalence subdivided by
measure type.
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suggesting that between half and two-thirds of all
ALS patients experience pain. Table 1 shows the
individual study data for pain prevalence ranged
from 19.4 to 92.0%. Smaller sample sizes present
larger confidence intervals indicating lower preci-
sion. Larger samples produce more reliable results.
Notably, Kehyayan et al. (25) produced a preva-
lence estimate close to the overall pooled pain
prevalence across all studies (represented by the
vertical dashed line in Figure 2); this study had
the largest sample size (N¼2092).
Figure 2 displays the subgroup analysis with
studies divided according to pain measure type.
Tailored measures for determining the prevalence
of pain in ALS were used in nine of the included
studies (18,20,22,23,27,31,33–35). Eight studies
used validated measures only (19,21,25,26,
28,30,36,37). Four studies used tailored measures
of pain supplemented by validated measures
(17,24,29,32). Both tailored measures and tailored
supplemented by validated measures showed con-
siderable heterogeneity (I2 ¼ 90%, p< 0.001 and
I2 ¼ 83%, p<0.001, respectively). There was a
larger disparity in pooled pain prevalence between
tailored measures, 47% (95% CI ¼ 34–60%), and
tailored supplemented by validated measures, 76%
(95% CI ¼ 56–89%). Only validated measures
showed a lower degree of heterogeneity (I2 ¼
82%, p¼0.002), but still relatively high. The
pooled pain prevalence of 65% (95% CI ¼
56–73%) of only validated measures was closest to
that of the overall pooled pain prevalence across
all studies of 60% (95% CI ¼ 50–69%).
Pain location
The location of pain was addressed in nine of the
included studies (19–23,26,29,30,33). A total of
393 participants reported 715 locations of pain
(see Supplementary Table 2 for details). Figure 3
shows location categories of pain from the nine
included studies. The most commonly reported
pain location was the upper limbs including
shoulders/extremities, followed by lower limbs
including extremities. Reports of pain in the head/
neck/trunk/back were lowest.
Pain characteristics
Intensity of pain was reported in seven of the
included studies by a total of 1426 participants
(18,19,21,24,25,28,29). However, data provided
were incomplete, with “severe pain” being
reported consistently across studies. From the total
number of participants reporting pain intensity
(N¼ 1426), moderate ratings were reported most
(78.8%, N¼ 1124), followed by severe ratings
(17.5%, N¼ 250). Mild and very severe intensity
pain were reported least (2.0%, N¼28 and 1.7%,
N¼ 24, respectively). In a more detailed examin-
ation, four of the studies (18,24,25,28) found the
majority of participants reported moderate pain,
ranging from 33.0% (N¼6) to 51.5% (N¼1077).
One study reported severe pain intensity at 13.8%
(N¼ 22) with no other pain categories listed (19)
and one other study showed that 65.4% (N¼17)
of participants experienced very severe pain (29).
Contrastingly, Hanisch et al. (21) found the great-
est proportion of participants reported mild pain at
58.0% (N¼ 21), with 39.0% (N¼ 14) having
moderate pain. See Supplementary Table 3 for
specific breakdown and details of pain intensity.
Specific types or source of pain were reported
in seven of the included studies
(18,21,26,27,30,32,33). Cramps and spasms were
the most commonly reported types of pain in six
of the included studies (18,21,27,30,32,33). Two
studies (18,32) directly examined muscular cramps
as the source of pain, and therefore 100%
(N¼ 264 and N¼32, respectively) of the pain
reported in these studies was related to cramps. A
further two studies (21,33) also included cramps
in their study. They reported that 63% (N¼29)
and 37.5% (N¼ 6) of individuals experienced pain
from cramps. Additionally, Ng et al. (27) found
72.7% (N¼ 32) of individuals experienced cramps
and/or spasms. Rivera et al. (30) reported only 9%
of individuals reported experiencing cramps.
Neuropathic pain was reported in three of the
included studies. One study used the Douleur
Neuropathique–4 [Neuropathic Pain Diagnostic
Questionnaire] and reported that 8.6% (N¼8) of
individuals with ALS experienced neuropathic pain
(26). Rivera et al. (30) utilized the Neuropathic
Pain Scale. They identified rates of neuropathic
pain descriptors, the highest being dull (22%), fol-
lowed by sharp (18%) and ache (14%). Taga et al.
(33) found 62.5% (N¼10) of participants
Figure 3. Locations of pain in subgroup of ALS pain
studies (N¼9).
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experienced pain with neuropathic-type descriptors
such as “electric shock”, “burning” “dull”,
“stabbing”, “throbbing”, “painful cold”, “sharp”,
“paroxysmal shooting” or “complex regional pain
syndrome”. An additional study (36), did not find
any patients with ALS reporting neuropathic pain.
Discussion
Pain is a prominent symptom with a diverse pres-
entation in ALS. Pooled pain prevalence in the
published ALS literature is 60% (95% CI ¼
50–69%) with a substantial level of between-study
heterogeneity. Studies using only validated meas-
ures showed a pain prevalence of 65%. Despite
between-study heterogeneity was marginally lower
for validated pain measures, it was still notably
high. There were many different validated pain
measures used in the included studies, and there
was minimal commonality between the measures
and administration methods. This introduces het-
erogeneity in assessment techniques and subse-
quently, heterogeneity in the prevalence estimates.
A number of studies (N¼9) used tailored
measures (e.g., face-to-face or clinical interviews,
un-validated questionnaire measures, or retrospect-
ive medical record reviews). These measures
showed the largest between-study heterogeneity.
Due to the lack of standardization for this type of
pain detection, the findings may be influenced by
factors such as variable reporting, inconsistent clas-
sification, and clinically-subjective identification.
Tailored measures produced the lowest pooled
prevalence of pain estimate (45%). This could
indicate a risk of observer or measurement bias,
resulting in the under-estimation of
pain prevalence.
A recent study also proposed that some indi-
viduals do not report pain due to it being regarded
as a minor symptom compared to other aspects of
the disease (3). This may further contribute to
under-reporting of pain, as individuals might not
be asked about their pain in a direct or structured
way. Conversely, in a small subset of studies,
when combining tailored with validated measures,
there was still a high level of between-study hetero-
geneity. This also suggests that this mixed method-
ology in identifying cases of pain might induce bias
and actually over-estimate prevalence of pain, as
shown by the 76% pooled prevalence estimate.
Due to under and over estimation of pain, both
may have repercussions for timely intervention and
selecting pharmacological or nonpharmacological
treatments. Standardized or equivalent validated
assessment methods of pain are needed in ALS, to
lower current levels of heterogeneity. Considering
the importance of pain to ALS patients, its poten-
tial in limiting participation in activities of daily liv-
ing and reducing quality of life (e.g., (21,29));
there is a clear need for increased attention from
clinicians and researchers. Consensus on which
tools should be used to assess, monitor and com-
pare symptoms of pain in an ALS-specific popula-
tion will increase the likelihood of ameliorating
distressing experiences of pain more effectively.
In terms of characteristics of pain, our findings
demonstrate that the most commonly reported
location of pain for ALS patients is in the upper
limbs, but can also occur in other regions, includ-
ing the lower limbs, head, back and neck. This
observation concurs with previous findings (9).
Future studies should look to map specific
regions(s) of ALS onset and the experience of
pain. This may provide further insight in to the
impact of the condition. Cramps and spasms were
the most commonly reported types or sources of
pain in ALS (38). A previous systematic review
found that that there was no evidence in favor of
particular interventions for the management of
muscle cramps (39) but the UK NICE guidelines
for assessment and management for ALS provide
some recommendations (5). However, they do not
discuss these recommendations in the general con-
text of pain.
Neuropathic pain, or pain with neuropathic-
type descriptors, was also reported in three of the
studies included in this review (26,30,33). It is
important to note that two of these studies (26,30)
used measures specifically designed to measure
neuropathic pain. The other study used qualitative
neuropathic-type descriptors (33). Of note, one
study (36) indicated that neuropathic pain is not
prevalent in ALS. This type of pain is often mech-
anistically complex and experienced unpredictably
by patients (40,41), but has several potential
pharmacological management pathways (42).
However, as described in a previous review (2)
there is limited exploration or understanding of
neuropathic pain or prevalence in ALS.
Pain is a personalized experience throughout
the trajectory of disease progression for people liv-
ing with ALS. It has been reported to span from
physical to mental pain (3). The qualitative experi-
ence of pain may be paramount in understanding
how people perceive, process and adapt to the
pain in their lives. As such, while standardized
detection and quantification of pain are important,
there should be flexibility to record specific qual-
ities and experiences of the pain. This will aid in
understanding the encompassing nature and
impacts of pain, as well as inform palliative care
needs at an individual patient level.
Limitations
There are several limitations to this review. Firstly,
there were fewer data and less information avail-
able for the pain characteristics (such as intensity
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and type) and location, primarily due to variable
and subjective reporting between and within stud-
ies. This resulted in merging of characteristics
based on common elements and this reductionism
of findings might limit conclusions. Future
research should look to characterize pain more
specifically in terms of etiology, source, intensity,
and type to further elucidate this symptom. Pain
was most commonly associated with cramps in the
research, which may have skewed the findings.
However, there were different sources of pain
reported throughout included studies.
Further research is needed to understand the
impact of experience of ALS patients longitudin-
ally over the course of the disease, in relation to
genetic phenotype, cognitive and behavioral
impairment. Further exploration of characteristics
and prevalence of pain across the motor neurone
disease spectrum (such as progressive muscular
atrophy, progressive bulbar palsy, flail limb syn-
drome, and primary lateral sclerosis) would be of
value. Due to the importance of first identifying
the prevalence of pain and its characteristics prior
to management, this review did not examine
pharmacological and nonpharmacological
approaches to treatment of pain in ALS. Future
research should include the preferences of ALS
patients in receiving treatment for pain.
Conclusion
This systematic review and meta-analysis indicate
that physical pain is a symptom occurring for two-
thirds of all ALS patients’ experience. Considering
the variability and heterogeneity in reported pain
prevalence and outcome measures used in the
included studies in this review, there is a clear
need for a standardized approach using validated
tools that have both clinical and research utility to
characterize and assess pain in ALS. Better charac-
terization of pain will support more effective man-
agement and treatment of this symptom to
promote increased quality of life and wellbeing in
ALS patients.
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